(aripiprazole) Approved by the FDA in 2002, Abilify is a top-selling drug prescribed to treat depression, bipolar disorder, schizophrenia, and Tourette syndrome. Post-marketing reports of pathological gambling and other reward-seeking behaviors have been reported in patients treated with Abilify, regardless of whether these patients had a prior history of gambling. Numerous studies have linked Abilify to compulsive gambling and hypersexuality, and both European and Canadian regulatory agencies have required the manufacturers of Abilify to add warnings regarding the risk of pathological gambling.